iX Biopharma (Catalist:42C) Revenue Growth Clashes With Wider Quarterly Losses

iX Biopharma went into this earnings release with a hot share price, up more than 30% over the past three months, and a rich P/B of 32.2x that already priced in a lot of hope. The headline from Q4 is less about growth and more about pressure. Revenue for the quarter sat at about S$2.1m while the company reported a net loss of roughly S$5.0m and another quarterly loss per share. For a stock this expensive on book value, the persistence of red ink is what the market now has to digest.

Love the potential of iX Biopharma but concerned about the ongoing losses at this valuation? Take a look at the list of solid balance sheet and fundamentals stocks (425 results) for stocks that pair stronger balance sheets with more resilient fundamentals.

Q4 2026 Earnings Summary

• Revenue (Q4 2026 vs. Q4 2025 PCP): S$2.089m vs. S$1.817m (higher quarterly revenue compared with the prior corresponding period)
• Net Loss (Q4 2026 vs. Q4 2025 PCP): S$5.021m loss vs. S$2.193m loss (wider quarterly loss compared with the prior corresponding period)
• Basic EPS (Q4 2026 vs. Q4 2025 PCP): S$0.004802 loss per share vs. S$0.002479 loss per share (larger quarterly loss per share compared with the prior corresponding period)
• Trailing Twelve Month Net Loss (TTM to Q4 2026 vs. TTM to Q4 2025 PCP): S$7.993m loss vs. S$10.141m loss (smaller loss over the latest twelve month period compared with the prior corresponding period)

Prefer clear charts instead of another wall of earnings figures and footnotes? See iX Biopharma's full financial picture with a visual view of its balance sheet strength and funding runway in the company report for iX Biopharma.

iX Biopharma’s Optionality Story Meets Mixed Signals

For investors attracted to iX Biopharma as a multi asset wafer platform, the latest figures send a mixed but not outright negative signal. Revenue of about S$2.1m in Q4 2026 is higher than the prior year quarter, which at least points to some commercial traction behind the story. Over the trailing twelve months the net loss is smaller than the prior period, hinting that the broader platform is not drifting further away from breakeven on this timeframe.

Losses Keep The iX Biopharma Risk Case Alive

The bear case around funding needs and execution risk still has plenty to work with. Q4 2026 brought a net loss of roughly S$5.0m, which is wider than the prior year quarter, and a larger loss per share. That tension between a smaller trailing twelve month loss and a weaker latest quarter will concern investors who want clearer progress toward sustainable profitability from iX Biopharma before giving the pipeline more credit.

After wider quarterly losses, past shareholder dilution and a volatile share price, you may want to review our risk analysis for iX Biopharma which shows 3 important warning signs

Stay Ahead With Simply Wall St

iX Biopharma’s wide Q4 loss against a high P/B ratio is exactly the kind of setup where timing and risk awareness matter. Register for free with Simply Wall St and add iX Biopharma to your Watchlist so you can track the share price against fair value estimates and watch for a more attractive entry point. Once you are invested, keep perspective with the Portfolio Command Center that cuts through noise and highlights only the key developments affecting your holdings. Round this out by tapping into the Community to see how other investors are thinking about catalysts and risks, so you can spot potential turning points early and stay ahead of the market.

Curious About Fresh Alternatives To iX Biopharma

Markets move fast and the next breakout stories rarely stay under the radar for long. Scan fresh stock ideas before the crowd catches on and act now.

• Target companies with strong momentum behind real earnings power by running through the curated list of 76 profitable AI stocks that aren't just burning cash before prices start flying.
• Zero in on potential inflation shelters by reviewing the hand picked group of 32 elite gold producer stocks while sentiment is still mixed and entry points may be dropping.
• Spot potential long term compounders early by checking the carefully filtered 114 top founder-led companies while these stories are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com